PI3Kδ inhibitors in cancer: rationale and serendipity merge in the clinic

Cancer Discovery
David A Fruman, Christian Rommel

Abstract

Several phosphoinositide 3-kinase (PI3K) inhibitors are in the clinic and many more are in preclinical development. CAL-101, a selective inhibitor of the PI3Kδ isoform, has shown remarkable success in certain hematologic malignancies. Although PI3Kδ signaling plays a central role in lymphocyte biology, the degree of single-agent therapeutic activity of CAL-101 during early-phase development has been somewhat unexpected. CAL-101 works in part by blocking signals from the microenvironment that normally sustain leukemia and lymphoma cells in a protective niche. As PI3Ks enter the arena of molecular-targeted therapies, CAL-101 provides proof of principle that isoform-selective compounds can be effective in selected cancer types and patient populations. A key question is whether compounds targeting a single PI3K catalytic isoform can provide meaningful single agent efficacy in cancer cells that express multiple isoforms. Clinical studies of the drug CAL-101 have provided a significant advance by showing that selective targeting of PI3Kδ achieves efficacy in chronic lymphocytic leukemia, in part through targeting the tumor microenvironment.

References

Jan 25, 1991·Cell·L C CantleyS Soltoff
Oct 6, 1998·Annual Review of Biochemistry·D A FrumanL C Cantley
Nov 1, 2001·Annual Review of Cell and Developmental Biology·R KatsoM D Waterfield
Jul 3, 2002·Nature Reviews. Cancer·Igor Vivanco, Charles L Sawyers
Sep 18, 2002·The Journal of Experimental Medicine·Elizabeth ClaytonMartin Turner
Mar 16, 2004·Science·Yardena SamuelsVictor E Velculescu
Aug 6, 2004·The Journal of Immunology : Official Journal of the American Association of Immunologists·Karin ReifJason G Cyster
Nov 3, 2004·Cancer Research·Ian G CampbellWayne A Phillips
Mar 18, 2005·Annual Review of Immunology·Jason G Cyster
Apr 9, 2005·Trends in Biochemical Sciences·Bart VanhaesebroeckLazaros C Foukas
Jun 14, 2005·Cancer Cell·Yardena SamuelsVictor E Velculescu
Aug 24, 2005·The Journal of Immunology : Official Journal of the American Association of Immunologists·Louise M C WebbMartin Turner
Oct 18, 2005·British Journal of Haematology·Marina BousquetPierre Brousset
Nov 24, 2005·Blood·Wojciech SwatThomas G Diacovo
Jan 25, 2006·Proceedings of the National Academy of Sciences of the United States of America·Sohye KangPeter K Vogt
Mar 7, 2006·Current Opinion in Immunology·Takaharu Okada, Jason G Cyster
Jul 19, 2006·Nature Reviews. Genetics·Jeffrey A EngelmanLewis C Cantley
Oct 4, 2006·The Journal of Immunology : Official Journal of the American Association of Immunologists·Klaus OkkenhaugBart Vanhaesebroeck
Nov 3, 2006·Nature Reviews. Drug Discovery·Thomas RückleChristian Rommel
Nov 4, 2006·The Journal of Immunology : Official Journal of the American Association of Immunologists·Daniel T PattonKlaus Okkenhaug
Jan 9, 2007·Trends in Immunology·Klaus OkkenhaugBart Vanhaesebroeck
Feb 6, 2007·The Journal of Immunology : Official Journal of the American Association of Immunologists·Monther M Al-AlwanAaron J Marshall
Feb 17, 2007·The Biochemical Journal·Severine I GharbiMichael D Waterfield
Sep 18, 2007·Nature Medicine·Teresa PalomeroAdolfo A Ferrando
Nov 13, 2007·Biochimica Et Biophysica Acta·Romina MaroneMatthias P Wymann
Nov 24, 2007·Autoimmunity Reviews·Dimitar G EfremovPablo G Longo
Feb 28, 2008·International Immunology·Tomomitsu DoiShigeo Koyasu

❮ Previous
Next ❯

Citations

Aug 11, 2012·Journal of Medicinal Chemistry·Felix Gonzalez-Lopez de TurisoTimothy D Cushing
Oct 20, 2012·Nature Immunology·Sabine Siegemund, Karsten Sauer
Jan 1, 2013·The Journal of Biological Chemistry·Lomon SoDavid A Fruman
May 16, 2013·Current Opinion in Hematology·Jonathan H SchatzH Guido Wendel
Sep 26, 2012·The Cancer Journal·Michael Y Choi, Thomas J Kipps
Nov 16, 2013·Science·Mary Ellen Conley, David A Fruman
May 16, 2013·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Britta WeigeltJulian Downward
Oct 25, 2014·Lung Cancer Management·Haiying ChengRoman Perez-Soler
Mar 29, 2014·Nature Communications·Qiangjun ZhouChang Chen
Jan 22, 2013·Annual Review of Immunology·Klaus Okkenhaug
Jun 13, 2013·Expert Opinion on Therapeutic Targets·Camilla EvangelistiAlberto M Martelli
Mar 16, 2013·Expert Opinion on Therapeutic Patents·William A Denny
Sep 24, 2015·Biochimie·Julien ViaudBernard Payrastre
Mar 1, 2012·The Biochemical Journal·Lomon So, David A Fruman
Mar 8, 2014·Oncoimmunology·Erika VacchelliLorenzo Galluzzi
Oct 22, 2013·Natural Product Reports·Armin Bauer, Mark Brönstrup
Apr 24, 2015·PLoS Computational Biology·Lorenza A D'AlessandroUrsula Klingmüller
Oct 25, 2016·Critical Reviews in Biochemistry and Molecular Biology·Julia Jellusova, Robert C Rickert
Mar 22, 2014·Cancer Cell·Bart Vanhaesebroeck, Asim Khwaja
Nov 15, 2014·Nature Reviews. Drug Discovery·Jeffrey R SkaarMichele Pagano
Aug 2, 2014·European Journal of Haematology·Vaclav Seda, Marek Mraz
Mar 23, 2017·Bioorganic & Medicinal Chemistry Letters·Minhang XinSan-Qi Zhang
Apr 23, 2013·Therapeutic Advances in Hematology·Jeremy L Warner, Jon E Arnason
Jul 26, 2013·Nature Reviews. Immunology·Robert C Rickert
Mar 13, 2015·Medicinal Research Reviews·Manman WeiAo Zhang
Jan 17, 2019·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Giuseppe Curigliano, Rashmi R Shah
Feb 12, 2019·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Ian W FlinnPier Luigi Zinzani
Mar 1, 2019·Biomolecules·Michelle S MillerSandra B Gabelli
Feb 1, 2014·Nature Reviews. Drug Discovery·David A Fruman, Christian Rommel

❮ Previous
Next ❯

Related Concepts

Related Feeds

B-Cell Leukemia (Keystone)

B-cell leukemia includes various types of lymphoid leukemia that affect B cells. Here is the latest research on B-cell leukemia.

AKT Pathway

This feed focuses on the AKT serine/threonine kinase, which is an important signaling pathway involved in processes such as glucose metabolism and cell survival.